Weekly Spotlight
CMS and FDA Launch RAPID Coverage Pathway — While IPPS Rule Proposes to Repeal a Parallel Device Payment Program
In a major development for the medical device industry, CMS and FDA jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway on April 23 — the first formal fast-track mechanism linking FDA market authorization to Medicare coverage in years. Under RAPID, manufacturers of FDA-designated breakthrough devices will engage both agencies early in development so that evidence generated for regulatory review can simultaneously support Medicare national coverage decisions, compressing a timeline that has historically stretched well over a year. CMS will pause the existing Transitional Coverage for Emerging Technologies (TCET) pathway for new applicants, consolidating breakthrough device coverage through the new structure. HHS Secretary Kennedy had hinted to lawmakers in mid-April that a TCET-related announcement was coming, but the scope of the RAPID announcement exceeded most industry expectations.
The cardiology sector stands to benefit disproportionately. Approximately 250 FDA breakthrough designations are in active cardiovascular device programs — the largest concentration of any specialty — spanning structural heart, electrophysiology, and imaging. Medtech trade groups including AdvaMed welcomed the announcement, while Healthcare Dive and MedTech Dive noted that implementation details — particularly on evidentiary standards and coverage scope — remain to be resolved in the 60-day public comment period via Federal Register notice.
The announcement, however, arrived alongside a significant complication. The FY 2027 Inpatient Prospective Payment System (IPPS) proposed rule, released April 10, proposes to repeal the alternative pathway for New Technology Add-on Payments (NTAP) for breakthrough devices beginning in FY 2028. The current alternative NTAP pathway allows breakthrough devices to qualify for Medicare add-on payments by demonstrating they are costly, without needing to prove substantial clinical improvement. The proposed repeal would require all technologies to clear the full clinical improvement bar. AdvaMed called the rollback “disappointing.” Comments on both the RAPID pathway and the IPPS rule are due June 9, 2026.
The net picture is one of structural ambiguity: the administration is accelerating the path from FDA authorization to Medicare coverage (RAPID) while simultaneously tightening the financial support available to devices once they are covered (NTAP repeal). For structural heart and EP device makers watching both announcements, the week underscored that breakthrough device policy is being rewritten on multiple fronts simultaneously — and that early engagement with both agencies under the new RAPID framework will be essential.Tags: #DEVICE
Centers for Medicare and Medicaid Services (CMS)
Medicaid Under Pressure: Work Requirements Live, Oz Launches 50-State Audit, MACPAC Raises Oversight Concerns
Medicaid dominated the policy landscape this week across federal and state levels. The One Big Beautiful Bill Act’s new work requirements took effect, requiring Medicaid applicants in expansion states to prove at least one month of work, school, or volunteering — with states allowed to demand up to three months. Indiana set the maximum three-month threshold first; CMS has not yet issued full implementation guidance, leaving states to navigate significant operational questions ahead of the January 1, 2027 federal deadline. States that previously tried work requirements through 1115 waivers — including Arkansas and Georgia — faced administrative failures and widespread coverage losses. Despite declining enrollment (down 4% nationally from December 2024 to December 2025), most states are proposing higher Medicaid budgets to cover rising per-enrollee costs and anticipated federal funding cuts. Simultaneously, CMS Administrator Dr. Oz announced a 50-state Medicaid provider revalidation directive, requiring states to submit plans within 30 days to audit high-risk providers — the most aggressive enrollment scrutiny in years. Adding a policy layer, MACPAC’s April meeting produced draft recommendations flagging a lack of transparency in how managed care plans deploy automated tools in prior authorization decisions, gaps in state and federal oversight of those systems, and the absence of Medicaid-specific pharmacy benefit manager regulation in the Consolidated Appropriations Act of 2026.- New Federal Medicaid Rules Require 1 Month of Work; Some States Demanding More – States and Insurers Await Federal Details on Medicaid Work Requirement Implementation – States Boosting Medicaid Budgets Even as Enrollments Decline – Governors and State Medicaid Directors Get a New Assignment from Dr. Oz – Dr. Oz Announces 50-State Audit of Medicaid Program Oversight – MACPAC: Draft Recommendations on Automation in Medicaid Prior Authorization – MACPAC: Draft Recommendations on Medicaid Managed Care Accountability Tags: #PATIENT #PROVIDER #PAYER #HOSPITAL
BALANCE Model Delayed Indefinitely; CMS Extends Medicare GLP-1 Bridge Program Through 2027
CMS paused the BALANCE demonstration model indefinitely after major insurers declined to participate, citing actuarial risk. The model was designed to formalize Medicare and Medicaid coverage pathways for GLP-1 obesity drugs. To prevent a coverage cliff for current participants, CMS extended its short-term Medicare GLP-1 bridge program through 2027 at a $50 beneficiary copay, while continuing to accept state Medicaid applications through July 31. The delay leaves the long-term Medicare obesity drug coverage framework unresolved.Source(s): CMS Pauses Weight-Loss BALANCE Model for Medicare, As Major Insurers Decline BALANCE Model, Consumer Group Urges HHS To Pivot, CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage Tags: #DRUG #PATIENT #PAYER
Medicare AI Prior Authorization Pilot Linked to Care Delays; CMS Signals Possible Tweaks
CMS’s WISeR AI-driven prior authorization pilot has been linked to care delays for Medicare patients in Washington state, with hospitals reporting procedures previously authorized in two weeks now taking four to eight weeks under the automated system. Sen. Maria Cantwell confronted HHS Secretary Kennedy during Senate HELP Committee hearings; Kennedy did not commit to suspending the pilot but said it would be reviewed. CMS Principal Deputy Administrator Chris Klomp separately acknowledged the model may need to be tweaked as Democratic and stakeholder opposition mounts.Source(s): Medicare AI Prior Authorization Pilot Delaying Care in Washington: Report, Federal Test of AI Prior Authorization Is Delaying Care for Seniors, Cantwell Grills RFK On WISeR Model Tags: #PATIENT #PROVIDER #PAYER
CMS Proposes Below-Inflation Hospital Payments for FY2027, Signals Mandatory Value-Based Expansion
CMS proposed a 2.4% operating payment rate increase for hospitals participating in quality reporting programs under the FY 2027 IPPS proposed rule — below the rate of inflation — while signaling plans to expand mandatory participation in value-based payment models, including nationalizing the CJR model into a mandatory program for joint replacement episodes. The proposed shift toward mandatory models could require hospitals in optional programs to accept downside financial risk, with particular implications for smaller, rural, and safety-net facilities. Comments are due June 9, 2026.Source(s): CMS Releases FY 2027 IPPS Proposed Rule: 2.4% Payment Increase, CJR Nationalization, Expanding the CJR Model Is Logical but Raises Implementation Concerns Tags: #HOSPITAL #PROVIDER
GAO: Federal Improper Payments Reached $186 Billion in FY2025
A new GAO report found that 15 federal agencies’ estimated improper payments totaled $186 billion in fiscal year 2025, an increase over prior years. CMS programs account for the largest share of improper payments across the federal government — a finding that arrives the same week Dr. Oz announced a 50-state Medicaid provider audit and is expected to fuel Republican arguments for enhanced program integrity measures in the reconciliation package.Source(s): Payment Integrity: Agencies’ Estimated Improper Payments Increased to $186 Billion in Fiscal Year 2025 Tags: #PATIENT #PAYER #HOSPITAL
Food and Drug Administration (FDA)
FDA Approvals This Week: Gene Therapy for Hearing Loss, New HIV Regimen, Expanded T1D Drug
The FDA issued three notable approvals this week spanning rare disease, infectious disease, and pediatric endocrinology. FDA granted accelerated approval to Otarmeni (lunsotogene parvec-cwha) from Regeneron for hearing loss caused by OTOF gene mutations — the first gene therapy approved in the United States for any form of genetic deafness, paired with the launch of FDA’s new Commissioner’s National Priority Voucher fast-track pilot. FDA also approved Merck’s Idvynso (doravirine and islatravir), a once-daily two-drug combination pill for adults with HIV-1 infection offering a new mechanism of action and simplified pill burden for stable patients. And FDA expanded the approved indication for teplizumab (Tzield, Sanofi) to include children as young as 1 year old to delay progression from preclinical to symptomatic stage 3 type 1 diabetes.- FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss – Regeneron Gets Landmark FDA Approval for First Gene Therapy for Hearing Loss – Merck Amps Up Presence in HIV Treatment Market with FDA Nod for Idvynso – FDA Expands Approval of Teplizumab to Include Children as Young as 1 Year Tags: #DRUG #PATIENT
FDA Accelerates Review of Psychedelic Treatments Following Executive Order
President Trump signed an executive order directing the FDA to conduct priority reviews of psychedelic drugs — including psilocybin, MDMA, and ibogaine — for serious mental illnesses. The FDA issued Commissioner’s National Priority Vouchers to three companies — Compass Pathways, Usona Institute, and Transcend Therapeutics — to fast-track regulatory timelines. The directive represents a significant shift in federal drug policy and is expected to reduce legal barriers for psychedelic clinical studies and increase federal research funding.Source(s): FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order, Trump Orders FDA Priority Reviews for Psychedelic Drugs, FDA Awards Three Priority Review Vouchers For Psychedelics Tags: #DRUG #PATIENT
FDA Issues Draft Guidance on Genome Editing Safety Standards for Gene Therapy
FDA released draft guidance on April 14 establishing safety assessment standards for genome editing technologies — including CRISPR — used in gene therapy development. The guidance addresses next-generation sequencing methods for detecting unintended genomic edits and proposes standards for evaluating off-target effects. Gene therapy programs represent one of the highest-volume categories of active FDA submissions. A public comment period is open.Source(s): FDA Issues Draft Guidance on Genome Editing Safety Standards for Gene Therapy Tags: #DRUG #DEVICE
FDA Clears AI Software for Mitral Valve Repair, Co-Developed with Edwards Lifesciences
FDA cleared Philips’ new AI-powered software for mitral valve repair, developed in close collaboration with Edwards Lifesciences. The software supports transcatheter mitral valve repair procedures by providing automated anatomical analysis and treatment planning support, marking a meaningful addition to the structural heart AI toolkit.Source(s): FDA Clears New AI Software for Mitral Valve Repair Tags: #DEVICE #PROVIDER
Former FDA Oncology Chief Warns of Growing Political Influence at the Agency
Richard Pazdur, MD, longtime director of the FDA’s Oncology Center of Excellence who retired in 2024, told the American Association for Cancer Research (AACR) annual meeting that he is concerned about growing political influence over FDA regulatory decisions and said he would not return to the agency under the current administration. His remarks landed the same week HHS Secretary Kennedy told senators that AI could eventually make FDA drug reviewers “irrelevant” — amplifying concern in the research and device communities about the agency’s scientific independence.Source(s): AACR: Former FDA Oncology Chief Pazdur Warns of Political Influence at the Agency, Kennedy Claims AI Drug Reviews Could Someday Make FDA ‘Irrelevant’ Tags: #DRUG #DEVICE
Department of Health and Human Services (HHS)
Kennedy Completes Senate Hearing Marathon: HHS Budget, Vaccines, CDC, and USPSTF All on the Table
HHS Secretary Robert F. Kennedy Jr. completed testimony before four Senate committees in one week, defending a proposed 12% HHS budget cut and tangling with lawmakers across a wide range of policy fronts. Kennedy declined to commit to backing CDC director nominee Erica Schwartz on vaccine recommendations, telling senators he did not discuss the pick with President Trump. He described the U.S. Preventive Services Task Force as “lackadaisical and negligent” — HHS subsequently published a Federal Register notice recruiting new USPSTF members, signaling a coming reorientation of the panel that sets preventive care coverage guidelines under the ACA. Separately, HHS blocked publication of a completed CDC study on COVID-19 vaccine effectiveness that reportedly found continued vaccine efficacy — adding to a pattern of scientific output being suppressed at federal health agencies. More than 130 medical and patient advocacy organizations raised alarm over recent changes to the CDC Advisory Committee on Immunization Practices charter.Source(s): RFK Jr. Defends HHS Tenure and 12% Budget Cut Proposal in Congressional Hearings, RFK Jr. Refused to Commit to Backing New CDC Director on Vaccines, HHS Seeks to Remake U.S. Preventive Services Task Force, HHS Blocks Publication of CDC Study on COVID-19 Vaccine Effectiveness, 130+ Health Groups Raise Alarm Over CDC Vaccine Panel Changes Tags: #ALL
TrumpRx Expands: Regeneron Offers Rare Disease Therapy Free; J&J Adds Four Drugs
The Trump administration announced its first completed TrumpRx drug pricing deal with Regeneron, under which the company will offer a rare disease therapy free of charge while providing discounts on additional products. Johnson & Johnson followed, adding four prescription medications to the TrumpRx platform. Senate Republicans blocked Democratic floor amendments during vote-a-rama that would have codified most-favored-nation pricing in statute or required public disclosure of TrumpRx deal terms. An independent analysis found Costco offered lower prices on several of the included drugs.Source(s): Trump Unveils Regeneron Deal to Lower Drug Prices, Regeneron Will Offer Rare Disease Therapy Free as Part of TrumpRx Deal, Johnson & Johnson To Launch On TrumpRx With 4 Of Its Prescription Drugs, GOP Blocks Amendments To Codify MFN, Disclose TrumpRx Deals Tags: #DRUG #PATIENT
RFK Jr. Aide Held $25M+ Stake in Wellness Company He Was Promoting at HHS
The New York Times reported that Calley Means, a senior health policy advisor to HHS Secretary Kennedy, held more than $25 million in equity in TrueMed — a wellness company that would directly benefit from expanded health savings account eligibility for wellness products — while simultaneously advocating for that policy within the administration. The disclosure prompted calls from Democratic lawmakers for a formal ethics review.Source(s): As Trump Officials Pushed Health Savings Accounts, RFK Jr. Aide Ran Wellness Company Poised to Benefit Tags: #DRUG #PATIENT
340B Rebate Pilot Draws Industry Fire; Legislative Reform Declared Dead for This Congress
The Trump administration’s new 340B rebate pilot — which would shift discounts from upfront price reductions to after-the-fact rebates — drew sharp opposition from the American Hospital Association, warning it would cost participating hospitals more than $1 billion annually. Drug manufacturers backed the rebate model as a transparency measure, producing a public standoff between industry groups. A bipartisan Senate effort to legislatively reform 340B is effectively dead for this Congress, leaving the program’s fundamental structure intact for now.Source(s): AHA Urges HRSA to Axe 340B Rebate Model That Would Cost Hospitals $1B+ per Year, Hospitals ‘Adverse to Transparency’ — Industry Groups Clash Over 340B Rebate Pilot, Providers Push Back on 340B Rebate Model, Federal 340B Drug Discount Program Overhaul Bill Unlikely to Pass This Congress Tags: #HOSPITAL #DRUG
NIH Slowdown Deepens: Funding Slows, Science Board Members Fired, Political Appointment to Advisory Council
Three developments underscored growing pressure on NIH’s independence and output. A New York Times analysis found NIH grant processing delays have reached six months or more, with some peer-review study sections meeting less frequently and downstream effects on biomedical research pipelines. President Trump fired multiple members of the National Science Board — the oversight body for the National Science Foundation — drawing bipartisan criticism. And Kristine Blanche, an integrative medicine doctor and spouse of acting Attorney General Todd Blanche, was appointed to an NIH advisory council on complementary and integrative health, with STAT News and KFF flagging potential conflict-of-interest concerns.Source(s): NIH Funding Pace Slows Further in Trump’s Second Year, Trump Fires Board Members Of Group That Oversees U.S. Science Funding, Kristine Blanche, Wife Of Acting Attorney General, Named To NIH Advisory Council Tags: #PROVIDER #DEVICE #DRUG
Heard on the Hill
Ways and Means Schedules Hospital CEO Hearing as Conservative Think Tank Targets Hospital Finances
The House Ways and Means Committee scheduled a full committee hearing with health system chief executives for April 28, expected to focus on hospital pricing, nonprofit tax-exemption obligations, charity care, and the relationship between hospital consolidation and Medicare payment rates. The hearing arrives as the Paragon Health Institute published a report arguing that hospitals are not broadly financially distressed and that federal policy overpays hospitals and enables consolidation. Hospital industry groups are on defense heading into the hearing.Source(s): Ways and Means Committee to Hear from Health System CEOs, April 28, Trump-Aligned Think Tank Calls for Major Changes to Federal Hospital Financing, Hospitals On Defense As Paragon, Consumers Target Sector, W&M Plans Hearing Tags: #HOSPITAL #PAYER #PROVIDER
House GOP Pushes ‘Reconciliation 3.0’ as Senate Democrats Frame Health Care Fight
House Republican leaders are working to build support for a slimmed-down Senate budget framework dubbed “Reconciliation 3.0,” seeking to advance additional fiscal priorities including further Medicaid changes. Senate Democrats are preparing a coordinated counter: Minority Leader Schumer announced plans to release a report documenting Trump-era damage to American health care, followed by a Democratic health care platform — a coordinated messaging strategy targeting competitive districts ahead of the 2026 midterms.Source(s): House GOP Leaders Scramble to Sell Senate’s Slimmed-Down Budget — ‘Reconciliation 3.0’, Schumer: Senate Democrats to Release Health Care Plan and White House Impact Report Tags: #PATIENT #PAYER #HOSPITAL
GOP Blocks MFN Amendments; PhRMA Calls Drug Pricing Codification Wrong
Senate Republicans voted down Democratic floor amendments during vote-a-rama that would have codified most-favored-nation drug pricing into statute or required public disclosure of TrumpRx deal terms. PhRMA’s top lobbyist told the POLITICO Health Summit that codifying MFN deals into law is “the wrong policy prescription” — a rare public alignment between the pharmaceutical industry and Senate Republicans against legislative permanence for the pricing program.Source(s): GOP Blocks Senate Amendments To Codify MFN Pricing and Disclose TrumpRx Deals, Top Drug Lobbyist Calls Trump’s Drug Pricing Codification ‘the Wrong Policy Prescription’ Tags: #DRUG #ALL
Senior GOP Appropriator Breaks With Trump Budget on NIH Cuts; House Advances FDA Spending Increase
A senior Republican member of the Senate Appropriations Committee publicly opposed the administration’s FY2027 NIH funding cuts, signaling bipartisan resistance within a unified Republican Congress. The House Appropriations Committee separately advanced an FDA budget of $7.1 billion for FY2027 — a $200 million increase — on a party-line vote, consistent with the GOP pattern of protecting FDA funding while cutting other HHS programs.Source(s): Top GOP Appropriator Opposed To Trump Budget’s NIH Funding Cuts, House Panel Advances FDA Spending Hike In Party-Line Vote Tags: #DRUG #DEVICE #PROVIDER
MAHA Movement Shows Political Cooling as PAC Runs Low on Cash
A New York Times analysis found that Make America Healthy Again voters are growing disillusioned as the administration has not fully delivered on MAHA priorities. A Politico investigation found the primary MAHA political action committee has reported only three donations this year, limiting the movement’s ability to support allied candidates in the 2026 midterms.Source(s): The ‘Make America Healthy Again’ Movement Is Cooling on Trump and Republicans, MAHA PAC’s Money Mystery Tags: #ALL
House Passes Telehealth Grants Reauthorization and Rural Care Act
The House passed three health access bills on April 21: H.R. 3419 reauthorizing federal telehealth network and resource center grant programs; H.R. 2493, the Improving Care in Rural America Reauthorization Act; and H.R. 2319, the Women and Lung Cancer Research Act. All three now move to the Senate.Source(s): House Passes Telehealth Grants Reauthorization and Rural Care Act Tags: #PATIENT #PROVIDER
Notable Notes
Valve Therapy: Earnings, Clinical Data, and Technology
A strong week of valve therapy news spanned commercial earnings, late-breaking clinical trial data, and device technology — collectively reinforcing the trend toward earlier and less invasive intervention across structural heart conditions. Edwards Lifesciences raised its full-year TAVR guidance to 7%–9% growth after Q1 TAVR sales hit $1.2 billion (up 14.4%), with CEO Bernard Zovighian citing a measurable clinical shift toward proactive disease management driven by EARLY TAVR trial momentum. New data from SCAI 2026 showed GLP-1 receptor agonists were associated with reduced heart attack and stroke rates in TAVR and PCI patients. AI-powered EHR alerts are improving TAVR referral rates and time to intervention at participating centers. On the surgical side, ten-year RECOVERY trial follow-up found early SAVR delivered a 3% vs. 24% composite cardiovascular mortality rate compared to watchful waiting in asymptomatic severe aortic stenosis — reinforcing the case for earlier intervention. The SURViV randomized trial showed transcatheter valve-in-valve replacement beat redo open surgery at one year in patients with failed bioprosthetic mitral valves (5.3% vs. 20.8% composite endpoint). And real-world data for transcatheter tricuspid valve replacement supported safety and efficacy outcomes consistent with clinical trial results in high-risk older adults.- Edwards Lifesciences Reports First Quarter Results – Edwards Raises 2026 Forecast as TAVR Sales Surge – Popular Weight Loss Drug Linked to Key Benefits for Patients Undergoing TAVR, PCI – GLP-1 Drugs Make Promising Debut in TAVR, Carotid Artery Stenting – AI-Powered EHR Alerts Make a World of Difference for Cardiologists, Heart Patients – RECOVERY Trial: Early SAVR Linked to Long-Term Survival Benefit Over Conservative Care – SURViV Trial: Transcatheter Valve-in-Valve vs. Redo Surgery for Failed Mitral Bioprostheses – Real-World Data Support Transcatheter Tricuspid Valve Replacement for Older Adults Tags: #DEVICE #PROVIDER #PATIENT
UnitedHealthcare Eliminates Most Prior Authorizations for Rural Providers
UnitedHealthcare announced it will exempt rural hospitals and critical access hospitals from most prior authorization requirements, accelerating payments by up to 50% for approximately 1,500 rural facilities. The move comes as prior authorization faces intense legislative and regulatory scrutiny and follows broader industry pressure after congressional hearings on the practice.Source(s): UnitedHealthcare Eliminates Most Prior Authorizations for Rural Providers, UnitedHealthcare Pares Back Prior Authorizations, Speeds Up Payments for Rural Providers Tags: #HOSPITAL #PAYER